



**FOR IMMEDIATE RELEASE**

## **Affimed to Present at the Jefferies 2018 London Healthcare Conference**

*Heidelberg, Germany, November 8, 2018* – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK cells, macrophages and T cells), today announced that Dr. Adi Hoess, CEO, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14, 2018 at 8:40 am GMT in London.

A live webcast of the conference presentation can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at <http://www.affimed.com/events.php>. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK cells, macrophages and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit [www.affimed.com](http://www.affimed.com).

### **Affimed Media Contact:**

Anca Alexandru, Head of Communications, EU IR  
E-Mail: [media@affimed.com](mailto:media@affimed.com)

### **Affimed Investor Contact:**

Gregory Gin, Head of Investor Relations

E-Mail: [IR@affimed.com](mailto:IR@affimed.com)